{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"CTC decline"},{"measurements":[{"groupId":"OG000","value":"24"}],"title":"CTC increased or No change/decline in CTC levels"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"The CTC marker will be used to evaluate efficacy of response to treatment. CTC changes will include changes from unfavorable (less than or equal to 5/7.5 ml) to favorable and declines by \\>30%.\n\nThree collections: before study initiation, Day 1 of Cycles 2 and 4","groups":[{"description":"Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.\n\nCarfilzomib: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.\n\nDexamethasone: Administered prior to administration of Study drug\n\nAcyclovir: Administered orally twice daily","id":"OG000","title":"Carfilzomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient did not have blood draw. 27 patients had blood draws for CTC enumeration across baseline, Cycle 2 day 1 and cycle 4 day 1.","reportingStatus":"POSTED","timeFrame":"Baseline through 36 months","title":"Number of Participants With Circulating Tumor Cell (CTC) Decline Over Three Time Points (Before Study Initiation, Day 1 of Cycles 2 and 4","type":"SECONDARY","unitOfMeasure":"Participants"}